Hospitals in the Catalonia region (Spain) have begun to select volunteers to participate in the phase 1 clinical trial with HIPRA’s vaccine in August 2021 – Photo: EFE
On September 11, within the framework of his visit to Finland, in the capital Helsinki, National Assembly Chairman Vuong Dinh Hue and members of the high-ranking delegation of the National Assembly of Vietnam attended the donation ceremony of medical supplies and equipment. COVID-19 prevention and control and economic cooperation agreements between Vietnamese and European enterprises on technology transfer for production and purchase of COVID-19 test kits, cooperation on clinical trials and Buy and sell COVID-19 vaccines.
Among the activities, T&T Pharmaceutical Joint Stock Company signed a cooperation agreement on technology transfer and production of Virella SARS-CoV-2 RT-PCR test kits in Vietnam with GERBION GmbH & Co. KG (Germany), signed a cooperation agreement with HIPRA Human Health SL U Company (Spain) on clinical trial and purchase of COVID-19 vaccine HIPRA SARS-CoV-2 with an expected number of 50 million dose, the total contract value is about 375 million euros (10,500 billion VND).
So COVID-19 vaccine by HIPRA What’s special?
According to the HIPRA website, HIPRA SARS-CoV-2 . vaccine is a “recombinant protein vaccine designed to optimize safety and induce a strong immune response that neutralizes the virus that causes COVID-19”.
HIPRA SARS-CoV-2 does not need to be stored at very low temperatures. This vaccine can be stored at temperatures between 2ºC and 8ºC, helping to facilitate transportation and distribution.
HIPRA expects clinical trials with this vaccine to be successfully completed, so that production can begin in October 2021 and delivery of the first 75 million doses by the end of this year.
HIPRA plans to produce 400 million doses of HIPRA SARS-CoV-2 vaccine in 2022 and reach 1.2 billion doses by 2023.
HIPRA says it has 50 years of experience developing vaccines. This pharmaceutical company owns manufacturing plants in Spain and Brazil.
On August 11, Spain’s Agency for Pharmaceuticals and Medical Products (AEMPS) granted permission to HIPRA to begin human clinical trials of its vaccine. This is the first time a Spanish COVID-19 vaccine has been approved for human trials.
Also in August, hospitals in the Catalonia region (Spain) began selecting volunteers to participate in the phase 1 clinical trial with this vaccine. After 21 days, the volunteers will receive a dose of 2.
The phase 1 clinical trial tested the vaccine’s safety, tolerability, immunogenicity (ability to induce an immune response), and effectiveness.